|
|---|
|
Salem ME,
Bodor JN,
Puccini A,
Xiu J,
Goldberg RM,
Grothey A,
Korn WM,
Shields AF,
Worrilow WM,
Kim ES,
Lenz HJ,
Marshall JL,
Hall MJ. Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors.
International Journal of Cancer.
. |
|
Arai H,
Elliott A,
Xiu J,
Wang J,
Battaglin F,
Kawanishi N,
Soni S,
Zhang W,
Millstein J,
Sohal D,
Goldberg RM,
Hall MJ,
Scott AJ,
Khushman M,
Hwang JJ,
Lou E,
Weinberg BA,
Marshall JL,
Lockhart AC,
Stafford P,
Zhang J,
Moretto R,
Cremolini C,
Korn WM,
Lenz HJ. The landscape of alterations in DNA damage response pathways in colorectal cancer.
Clin Cancer Res. 2021 Mar 25
. |
|
Hunt A,
Handorf E,
Blau M,
Chertock Y,
Fang C,
Hall MJ,
Jain R. Psychological distress in patients with metastatic cancer enrolling on phase I clinical trials.
J Cancer Surviv. 2021 Mar 13
:1-5. PMC ID:PMC7955695. |
|
Moslim MA,
Hall MJ,
Meyer JE,
Reddy SS. Pancreatic cancer in the era of COVID-19 pandemic: Which one is the lesser of two evils?.
World J Clin Oncol. 2021 Feb 24;12(2)
:54-60. PMC ID:PMC7918523. |
|
Abraham JP,
Magee D,
Cremolini C,
Antoniotti C,
Halbert DD,
Xiu J,
Stafford P,
Berry DA,
Oberley MJ,
Shields AF,
Marshall JL,
Salem ME,
Falcone A,
Grothey A,
Hall MJ,
Venook AP,
Lenz HJ,
Helmstetter A,
Korn WM,
Spetzler DB. Clinical validation of a machine-learning derived signature predictive of outcomes from first-line oxaliplatin-based chemotherapy in advanced colorectal cancer.
Clin Cancer Res. 2021 Feb 15;27(4)
:1174-1183. |
|
Hall MJ,
Bernhisel R,
Hughes E,
Larson K,
Rosenthal ET,
Singh NA,
Lancaster JM,
Kurian AW. Germline pathogenic variants in the Ataxia Telangiectasia Mutated (ATM) gene are associated with high and moderate risks for multiple cancers.
Cancer Prev Res (Phila). 2021 Jan 28
. |
|
Ward WH,
Meeker CR,
Handorf E,
Hill MV,
Einarson M,
Alpaugh RK,
Holden TL,
Astsaturov I,
Denlinger CS,
Hall MJ,
Reddy SS,
Sigurdson ER,
Dotan E,
Zibelman M,
Meyer JE,
Farma JM,
Vijayvergia N. Feasibility of Fitness Tracker Usage to Assess Activity Level and Toxicities in Patients With Colorectal Cancer.
JCO Clin Cancer Inform. 2021 Jan;5
:125-133. |
|
Salem ME,
Bodor JN,
Puccini A,
Xiu J,
Goldberg RM,
Grothey A,
Korn WM,
Shields AF,
Worrilow WM,
Kim ES,
Lenz HJ,
Marshall JL,
Hall MJ. Relationship between MLH1, PMS2, MSH2, and MSH6 gene specific alterations and tumor mutational burden (TMB) in 1,057 microsatellite instability-high solid tumors.
Int J Cancer. 2020 Nov 15;147(10)
:2948-2956. PMC ID:PMC7530095. |
|
Seeber A,
Zimmer K,
Kocher F,
Puccini A,
Xiu J,
Nabhan C,
Elliott A,
Goldberg RM,
Grothey A,
Shields AF,
Battaglin F,
El-Deiry WS,
Philip PA,
Marshall JL,
Hall M,
Korn WM,
Lenz HJ,
Wolf D,
Feistritzer C,
Spizzo G. Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma.
ESMO Open. 2020 Nov;5(6)
. PMC ID:PMC7684832. |
|
Tricarico R,
Nicolas E,
Hall MJ,
Golemis EA. X- and Y-linked chromatin-modifying genes as regulators of sex-specific cancer incidence and prognosis.
Clin Cancer Res. 2020 Nov;26(21)
:5567-5578. PMC ID:PMC7642178. |
|
McGillivray E,
Farma J,
Savage M,
Hall MJ,
Luo B,
Jain R. Pathologic Complete Response in Patient With ATM Mutation After Neoadjuvant FOLFOXIRI Plus Panitumumab Therapy for Locally Advanced Colon Cancer: A Case Report.
Clin Colorectal Cancer. 2020 Sep 18
. |
|
Hartman TR,
Demidova EV,
Lesh RW,
Hoang L,
Richardson M,
Forman A,
Kessler L,
Speare V,
Golemis EA,
Hall MJ,
Daly MB,
Arora S. Prevalence of pathogenic variants in DNA damage response and repair genes in patients undergoing cancer risk assessment and reporting a personal history of early-onset renal cancer.
Sci Rep. 2020 Aug 11;10(1)
:13518. |
|
Kilbride MK,
Egleston BL,
Hall MJ,
Patrick-Miller LJ,
Daly MB,
Ganschow P,
Grana G,
Olopade OI,
Fetzer D,
Brandt A,
Chambers R,
Clark DF,
Forman A,
Gaber R,
Gulden C,
Horte J,
Long JM,
Lucas T,
Madaan S,
Mattie K,
McKenna D,
Montgomery S,
Nielsen S,
Powers J,
Rainey K,
Rybak C,
Savage M,
Seelaus C,
Stoll J,
Stopfer JE,
Yao XS,
Domchek SM,
Bradbury AR. Longitudinal follow-up after telephone disclosure in the randomized COGENT study.
Genet Med. 2020 Aug;22(8)
:1401-1406. PMC ID:PMC7396300. |
|
Heald B,
Hampel H,
Church J,
Dudley B,
Hall MJ,
Mork ME,
Singh A,
Stoffel E,
Stoll J,
You YN,
Yurgelun MB,
Kupfer SS. Collaborative Group of the Americas on Inherited Gastrointestinal Cancer Position statement on multigene panel testing for patients with colorectal cancer and/or polyposis.
Fam Cancer. 2020 Jul;19(3)
:223-239. PMC ID:PMC7326311. |
|
Spizzo G,
Puccini A,
Xiu J,
Goldberg RM,
Grothey A,
Shields AF,
Arora SP,
Khushmann M,
Salem ME,
Battaglin F,
Baca Y,
El-Deiry WS,
Philip PA,
Nassem M,
Hall M,
Marshall JL,
Kocher F,
Amann A,
Wolf D,
Korn WM,
Lenz H,
Seeber A. Molecular profile of BRCA-mutated biliary tract cancers.
ESMO Open. 2020 Jun;5(3)
. PMC ID:PMC7312328. |
|
Golan T,
Kindler HL,
Park JO,
Reni M,
Macarulla T,
Hammel P,
Van Cutsem E,
Arnold D,
Hochhauser D,
McGuinness D,
Locker GY,
Goranova T,
Schatz P,
Liu YZ,
Hall MJ. Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial.
J Clin Oncol. 2020 May 1;38(13)
:1442-1454. |
|
Vijayvergia N,
Dasari A,
Deng M,
Litwin S,
Al-Toubah T,
Alpaugh RK,
Dotan E,
Hall MJ,
Ross NM,
Runyen MM,
Denlinger CS,
Halperin DM,
Cohen SJ,
Engstrom PF,
Strosberg JR. Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials.
Br J Cancer. 2020 Mar 10;122(9)
:1309-1314. PMC ID:PMC7188798. |
|
Biller LH,
Ukaegbu C,
Dhingra TG,
Burke CA,
Chertock Y,
Chittenden A,
Church JM,
Koeppe ES,
Leach BH,
Levinson E,
Lim RM,
Lutz M,
Salo-Mullen E,
Sheikh R,
Idos G,
Kastrinos F,
Stoffel E,
Weiss JM,
Hall MJ,
Kalady MF,
Stadler ZK,
Syngal S,
Yurgelun MB. A Multi-Institutional Cohort of Therapy-Associated Polyposis in Childhood and Young Adulthood Cancer Survivors.
Cancer Prev Res (Phila). 2020 Feb 12;13(3)
:291-298. PMC ID:PMC7060102. |
|
Jain R,
Handorf E,
Khare V,
Blau M,
Chertock Y,
Hall MJ. Impact of Baseline Nutrition and Exercise Status on Toxicity and Outcomes in Phase I and II Oncology Clinical Trial Participants.
Oncologist. 2020 Feb;25(2)
:161-169. PMC ID:PMC7011642. |
|
Reinacher-Schick AC,
Kindler HL,
Hammel P,
Reni M,
Van Cutsem E,
Mercade TM,
Hall MJ,
Park JO,
Hochhauser D,
Oh DY,
Tortora G,
Algul H,
O'Reilly EM,
McGuinness D,
Cui K,
Schlienger K,
Locker GY,
Golan T,
Arnold D. POLO: Efficacy and Health-Related Quality of Life (HRQOL) with Maintenance Olaparib Following First-Line Platinum-Based Chemotherapy (PBC) in Patients (PTS) with a Germline BRCA Mutation and Metastatic Pancreatic Cancer (MPC).
Oncology Research and Treatment. 2020 Feb;43
:68-68. |
|
Hammel P,
Kindler HL,
Reni M,
Cutsem EV,
Macarulla T,
Hall MJ,
Park JO,
Hochhauser D,
Arnold D,
Oh DY,
Reinacher-Schick A,
Tortora G,
Algul H,
O'Reilly EM,
McGuinness D,
Cui KY,
Joo S,
Yoo HK,
Patel N,
Golan T. Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib.
Ann Oncol. 2019 Dec 1;30(12)
:1959-1968. PMC ID:PMC6938600. |
|
Trabucco SE,
Gowen K,
Maund SL,
Sanford E,
Fabrizio DA,
Hall MJ,
Yakirevich E,
Gregg JP,
Stephens PJ,
Frampton GM,
Hegde PS,
Miller VA,
Ross JS,
Hartmaier RJ,
Huang SA,
Sun JX. A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability (MSI) and Pan-Tumor Characterization of One Thousand MSI-High Cases in 67,000 Patient Samples.
J Mol Diagn. 2019 Nov;21(6)
:1053-1066. |
|
Gupta S,
Provenzale D,
Llor X,
Halverson AL,
Grady W,
Chung DC,
Haraldsdottir S,
Markowitz AJ,
Slavin TP Jr,
Hampel H,
Ness RM,
Weiss JM,
Ahnen DJ,
Chen LM,
Cooper G,
Early DS,
Giardiello FM,
Hall MJ,
Hamilton SR,
Kanth P,
Klapman JB,
Lazenby AJ,
Lynch PM,
Mayer RJ,
Mikkelson J,
Peter S,
Regenbogen SE,
Dwyer MA,
Ogba N. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 2.2019.
J Natl Compr Canc Netw. 2019 Sep 1;17(9)
:1032-1041. |
|
Golan T,
Hammel P,
Reni M,
Van Cutsem E,
Macarulla T,
Hall MJ,
Park JO,
Hochhauser D,
Arnold D,
Oh DY,
Reinacher-Schick A,
Tortora G,
Algul H,
O'Reilly EM,
McGuinness D,
Cui KY,
Schlienger K,
Locker GY,
Kindler HL. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
N Engl J Med. 2019 Jul 25;381(4)
:317-327. PMC ID:PMC6810605. |
|
Golan T,
Hammel P,
Reni M,
Van Cutsem E,
Macarulla T,
Hall M,
Park J,
Hochhauser D,
Arnold D,
Oh D,
Reinacher-Schick A,
Tortora G,
Algul H,
O'Reilly E,
McGuinness D,
Cui K,
Schlienger K,
Locker G,
Kindler H. Olaparib as maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA mutation and metastatic pancreatic cancer: phase III POLO trial.
Ann Oncol. 2019 Jul;30 Suppl 4
:iv152. |
|
Nicolas E,
Tricarico R,
Savage M,
Golemis EA,
Hall MJ. Disease-Associated Genetic Variation in Human Mitochondrial Protein Import.
Am J Hum Genet. 2019 May 2;104(5)
:784-801. PMC ID:PMC6506819. |
|
Nicolas E,
Demidova EV,
Iqbal W,
Serebriiskii IG,
Vlasenkova R,
Ghatalia P,
Zhou Y,
Rainey K,
Forman AF,
Dunbrack RL Jr,
Golemis EA,
Hall MJ,
Daly MB,
Arora S. Interaction of germline variants in a family with a history of early-onset clear cell renal cell carcinoma.
Mol Genet Genomic Med. 2019 Mar;7(3)
:e556. PMC ID:PMC6418363. |
|
Beri N,
Patrick-Miller LJ,
Egleston BL,
Hall MJ,
Domchek SM,
Daly MB,
Ganschow P,
Grana G,
Olopade OI,
Fetzer D,
Brandt A,
Chambers R,
Clark DF,
Forman A,
Gaber R,
Gulden C,
Horte J,
Long J,
Lucas T,
Madaan S,
Mattie K,
McKenna D,
Montgomery S,
Nielsen S,
Powers J,
Rainey K,
Rybak C,
Savage M,
Seelaus C,
Stoll J,
Stopfer JE,
Yao XS,
Bradbury AR. Preferences for in-person disclosure: Patients declining telephone disclosure characteristics and outcomes in the multicenter Communication Of GENetic Test Results by Telephone study.
Clin Genet. 2019 Feb;95(2)
:293-301. PMC ID:PMC6453119. |
|
Provenzale D,
Gupta S,
Ahnen DJ,
Markowitz AJ,
Chung DC,
Mayer RJ,
Regenbogen SE,
Blanco AM,
Bray T,
Cooper G,
Early DS,
Ford JM,
Giardiello FM,
Grady W,
Hall MJ,
Halverson AL,
Hamilton SR,
Hampel H,
Klapman JB,
Larson DW,
Lazenby AJ,
Llor X,
Lynch PM,
Mikkelson J,
Ness RM,
Slavin TP Jr,
Sugandha S,
Weiss JM,
Dwyer MA,
Ogba N. NCCN Guidelines Insights: Colorectal Cancer Screening, Version 1.2018.
J Natl Compr Canc Netw. 2018 Aug;16(8)
:939-949. |
|
Hall MJ,
Morris AM,
Sun W. Precision Medicine Versus Population Medicine in Colon Cancer: From Prospects of Prevention, Adjuvant Chemotherapy, and Surveillance.
Am Soc Clin Oncol Educ Book. 2018 May 23;38(38)
:220-230. |
|
Gray PN,
Tsai P,
Chen D,
Wu S,
Hoo J,
Mu W,
Li B,
Vuong H,
Lu HM,
Batth N,
Willett S,
Uyeda L,
Shah S,
Gau CL,
Umali M,
Espenschied C,
Janicek M,
Brown S,
Margileth D,
Dobrea L,
Wagman L,
Rana H,
Hall MJ,
Ross T,
Terdiman J,
Cullinane C,
Ries S,
Totten E,
Elliott AM. TumorNext-Lynch-MMR: A comprehensive next generation sequencing assay for the detection of germline and somatic mutations in genes associated with mismatch repair deficiency and Lynch syndrome.
Oncotarget. 2018 Apr 17;9(29)
:20304-20322. PMC ID:PMC5945525. |
|
Meropol NJ,
Feng Y,
Grem JL,
Mulcahy MF,
Catalano PJ,
Kauh JS,
Hall MJ,
Saltzman JN,
George TJ Jr,
Zangmeister J,
Chiorean EG,
Cheema PS,
O'Dwyer PJ,
Benson AB 3rd. Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG-ACRIN Cancer Research Group (E4203).
Cancer. 2018 Feb 15;124(4)
:688-697. PMC ID:PMC6226304. |
|
Shaikh T,
Handorf EA,
Meyer JE,
Hall MJ,
Esnaola NF. Mismatch Repair Deficiency Testing in Patients With Colorectal Cancer and Nonadherence to Testing Guidelines in Young Adults.
JAMA Oncol. 2018 Feb 8;4(2)
:e173580. PMC ID:PMC5838708. |
|
Graves KD,
Hall MJ,
Tercyak KP. Introduction to the special issue on clinical and public health genomics: Opportunities for translational behavioral medicine research, practice, and policy.
Transl Behav Med. 2018 Jan 29;8(1)
:4-6. PMC ID:PMC6065537. |
|
Bradbury AR,
Patrick-Miller LJ,
Egleston BL,
Hall MJ,
Domchek SM,
Daly MB,
Ganschow P,
Grana G,
Olopade OI,
Fetzer D,
Brandt A,
Chambers R,
Clark DF,
Forman A,
Gaber R,
Gulden C,
Horte J,
Long JM,
Lucas T,
Madaan S,
Mattie K,
McKenna D,
Montgomery S,
Nielsen S,
Powers J,
Rainey K,
Rybak C,
Savage M,
Seelaus C,
Stoll J,
Stopfer JE,
Yao XS. Randomized Noninferiority Trial of Telephone vs In-Person Disclosure of Germline Cancer Genetic Test Results.
J Natl Cancer Inst. 2018 Sept 1;110(9)
:985-993. PMC ID:PMC6136932. |
|
Gupta S,
Provenzale D,
Regenbogen SE,
Hampel H,
Slavin TP Jr,
Hall MJ,
Llor X,
Chung DC,
Ahnen DJ,
Bray T,
Cooper G,
Early DS,
Ford JM,
Giardiello FM,
Grady W,
Halverson AL,
Hamilton SR,
Klapman JB,
Larson DW,
Lazenby AJ,
Lynch PM,
Markowitz AJ,
Mayer RJ,
Ness RM,
Samadder NJ,
Shike M,
Sugandha S,
Weiss JM,
Dwyer MA,
Ogba N. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 3.2017.
J Natl Compr Canc Netw. 2017 Dec;15(12)
:1465-1475. |
|
Hall MJ,
Forman AD,
Obeid E. The Hereditary Paraganglioma-Pheochromocytoma Syndrome: No Time to Waste.
JAMA Oncol. 2017 Dec 1;3(12)
:1739-1740. |
|
Meeker CR,
Wong YN,
Egleston BL,
Hall MJ,
Plimack ER,
Martin LP,
Von Mehren M,
Lewis BR,
Geynisman DM. Distress and financial distress in adults with cancer: An age-based analysis.
J Natl Compr Canc Netw. 2017 Oct;15(10)
:1224-1233. PMC ID:PMC7569506. |
|
Ramamurthy C,
Chertock Y,
Hall MJ. Randomized Controlled Trials in Hereditary Cancer Syndromes.
Surgical Oncology Clinics of North America. 2017 Oct;26(4)
:729-750. |
|
Obeid EI,
Hall MJ,
Daly MB. Multigene Panel Testing and Breast Cancer Risk: Is It Time to Scale Down?.
JAMA Oncol. 2017 Sep 1;3(9)
:1176-1177. |
|
Arora S,
Huwe PJ,
Sikder R,
Shah M,
Browne AJ,
Lesh R,
Nicolas E,
Deshpande S,
Hall MJ,
Dunbrack RL Jr,
Golemis EA. Functional analysis of rare variants in mismatch repair proteins augments results from computation-based predictive methods.
Cancer Biol Ther. 2017 Jul 3;18(7)
:519-533. PMC ID:PMC5639829. |
|
Hall MJ,
Obeid E,
Daly MB. Multigene Panels to Evaluate Hereditary Cancer Risk: Reckless or Relevant?.
J Clin Oncol. 2016 Dec;34(34)
:4186-4187. |
|
Vijayvergia N,
Li T,
Wong YN,
Hall MJ,
Cohen SJ,
Dotan E. Chemotherapy use and adoption of new agents is affected by age and comorbidities in patients with metastatic colorectal cancer.
Cancer. 2016 Oct 15;122(20)
:3191-3198. PMC ID:PMC5048504. |
|
Dotan E,
Alpaugh RK,
Ruth K,
Negin BP,
Denlinger CS,
Hall MJ,
Astsaturov I,
McAleer C,
Halbherr T,
Fittipaldi P,
Thrash-Bingham C,
Meropol NJ,
Cohen SJ. Prognostic Significance of MUC-1 in Circulating Tumor Cells in Patients With Metastatic Pancreatic Adenocarcinoma.
Pancreas. 2016
Sep;45(8)
:1131-5. PMC ID:PMC4983223. |
|
Meeker CR,
Geynisman DM,
Egleston BL,
Hall MJ,
Mechanic KY,
Bilusic M,
Plimack ER,
Martin LP,
von Mehren M,
Lewis B,
Wong YN. Relationships Among Financial Distress, Emotional Distress, and Overall Distress in Insured Patients With Cancer.
J Oncol Pract. 2016 Jun 21;12(7)
:e755-64. PMC ID:PMC5015446. |
|
Jain R,
Savage MJ,
Forman AD,
Mukherji R,
Hall MJ. The Relevance of Hereditary Cancer Risks to Precision Oncology: What Should Providers Consider When Conducting Tumor Genomic Profiling?.
J Natl Compr Canc Netw. 2016 Jun;14(6)
:795-806. |
|
Hall MJ,
Obeid EI,
Schwartz SC,
Mantia-Smaldone G,
Forman AD,
Daly MB. Genetic testing for hereditary cancer predisposition: BRCA1/2, Lynch syndrome, and beyond.
Gynecol Oncol. 2016 Mar;140(3)
:565-74. PMC ID:PMC4767686. |
|
Meyer JE,
Cohen SJ,
Ruth KJ,
Sigurdson ER,
Hall MJ. Young Age Increases Risk of Lymph Node Positivity in Early-Stage Rectal Cancer.
J Natl Cancer Inst. 2016 Jan;108(1)
. PMC ID:PMC4715232. |
|
Boland PM,
Ruth K,
Matro JM,
Rainey KL,
Fang CY,
Wong YN,
Daly MB,
Hall MJ. Genetic counselors' (GC) knowledge, awareness, understanding of clinical next-generation sequencing (NGS) genomic testing.
Clinical Genetics. 2015 Dec 19;88(6)
:565-72. PMC ID:PMC4474774. |
|
Nicolas E,
Arora S,
Zhou Y,
Serebriiskii IG,
Andrake MD,
Handorf ED,
Bodian DL,
Vockley JG,
Dunbrack RL,
Ross EA,
Egleston BL,
Hall MJ,
Golemis EA,
Giri VN,
Daly MB. Systematic evaluation of underlying defects in DNA repair as an approach to case-only assessment of familial prostate cancer.
Oncotarget. 2015 Nov 24;6(37)
:39614-33. PMC ID:PMC4741850. |
|
Guindalini RS,
Win AK,
Gulden C,
Lindor NM,
Newcomb PA,
Haile RW,
Raymond V,
Stoffel E,
Hall M,
Llor X,
Ukaegbu CI,
Solomon I,
Weitzel J,
Kalady M,
Blanco A,
Terdiman J,
Shuttlesworth GA,
Lynch PM,
Hampel H,
Lynch HT,
Jenkins MA,
Olopade OI,
Kupfer SS. Mutation Spectrum and Risk of Colorectal Cancer in African American Families with Lynch Syndrome.
Gastroenterology. 2015 Nov;149(6)
:1446-53. PMC ID:PMC4648287. |
|
Arora S,
Yan H,
Cho I,
Fan HY,
Luo B,
Gai X,
Bodian DL,
Vockley JG,
Zhou Y,
Handorf E,
Egleston BL,
Andrake M,
Nicolas E,
Serebriiskii I,
Yen TJ,
Hall MJ,
Golemis EA,
Enders GH. Genetic Variants That Presdispose to DNA Double-strand Breaks in Lymphocytes from a Subset of Patients With Familial Colorectal Carcinomas.
Gastroenterology. 2015 Sep 4;149(7)
:1872-1883 e9. |
|
Wani S,
Hall M,
Keswani RN,
Aslanian HR,
Casey B,
Burbridge R,
Chak A,
Chen AM,
Cote G,
Edmundowicz SA,
Faulx AL,
Hollander TG,
Lee LS,
Mullady D,
Murad F,
Muthusamy VR,
Pfau PR,
Scheiman JM,
Tokar J,
Wagh MS,
Watson R,
Early D. Variation in Aptitude of Trainees in Endoscopic Ultrasonography, Based on Cumulative Sum Analysis.
Clin Gastroenterol Hepatol. 2015 Jul;13(7)
:1318-1325 e2. PMC ID:PMC5511035. |
|
Bradbury AR,
Patrick-Miller L,
Long J,
Powers J,
Stopfer J,
Forman A,
Rybak C,
Mattie K,
Brandt A,
Chambers R,
Chung WK,
Churpek J,
Daly MB,
Digiovanni L,
Farengo-Clark D,
Fetzer D,
Ganschow P,
Grana G,
Gulden C,
Hall M,
Kohler L,
Maxwell K,
Merrill S,
Montgomery S,
Mueller R,
Nielsen S,
Olopade O,
Rainey K,
Seelaus C,
Nathanson KL,
Domchek SM. Development of a tiered and binned genetic counseling model for informed consent in the era of multiplex testing for cancer susceptibility.
Genetics in Medicine. 2015 Jun;17(6)
:485-492. |
|
Hall MJ,
Innocent J,
Rybak C,
Veloski C,
Scott WJ,
Wu H,
Ridge JA,
Hoffman JP,
Borghaei H,
Turaka A,
Daly MB. Bilateral granulosa cell tumors: a novel malignant manifestation of multiple endocrine neoplasia 1 syndrome found in a patient with a rare menin in-frame deletion.
Appl Clin Genet. 2015 ;8
:69-73. PMC ID:PMC4337709. |
|
Hall MJ,
Ruth KJ,
Chen DY,
Gross LM,
Giri VN. Interest in genomic SNP testing for prostate cancer risk: a pilot survey.
Hered Cancer Clin Pract. 2015 ;13(1)
:11. PMC ID:PMC4396119. |
|
Hall MJ,
Forman AD,
Montgomery SV,
Rainey KL,
Daly MB. Understanding Patient and Provider Perceptions and Expectations of Genomic Medicine.
J Surg Oncol. 2015 Jan;111(1)
:9-17. PMC ID:PMC4286413. |
|
Matro JM,
Ruth KJ,
Wong YN,
McCully KC,
Rybak CM,
Meropol NJ,
Hall MJ. Cost sharing and hereditary cancer risk: predictors of willingness-to-pay for genetic testing.
J Genet Couns. 2014 Dec;23(6)
:1002-11. PMC ID:PMC4420173. |
|
Hall MJ,
Herda MM,
Handorf EA,
Rybak CC,
Keleher CA,
Siemon M,
Daly MB. Direct-to-patient disclosure of results of mismatch repair screening for Lynch syndrome via electronic personal health record: a feasibility study.
Genet Med. 2014 Nov;16(11)
:854-61. PMC ID:PMC4216634. |
|
Konski A,
Meyer JE,
Joiner M,
Hall MJ,
Philip P,
Shields A,
McSpadden E,
Choi M,
Adaire B,
Duncan G,
Meropol NJ,
Cescon TP,
Cohen SJ. Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or limited metastatic pancreatic cancer.
Radiother Oncol. 2014 Oct;113(1)
:35-40. |
|
Hall MJ,
Forman AD,
Pilarski R,
Wiesner G,
Giri VN. Gene Panel Testing for Inherited Cancer Risk.
J Natl Compr Canc Netw. 2014 Sep;12(9)
:1339-1346. |
|
Dotan E,
Li T,
Hall MJ,
Meropol NJ,
Beck JR,
Wong YN. Oncologists' response to new data regarding the use of epidermal growth factor receptor inhibitors in colorectal cancer.
J Oncol Pract. 2014 Sep;10(5)
:308-14. |
|
Hall MJ. Conflicted confidence: academic oncologists' views on multiplex pharmacogenomic testing.
J Clin Oncol. 2014 May 1;32(13)
:1290-2. |
|
Thomay AA,
Nagorney DM,
Cohen SJ,
Sigurdson ER,
Truty MJ,
Burtness B,
Hall MJ,
Chun YS. Modern chemotherapy mitigates adverse prognostic effect of regional nodal metastases in stage IV colorectal cancer.
J Gastrointest Surg. 2014 Jan;18(1)
:69-74. |
|
Jones KA,
Kim PD,
Patel BB,
Kelsen SG,
Braverman A,
Swinton DJ,
Gafken PR,
Jones LA,
Lane WS,
Neveu JM,
Leung HCE,
Shaffer SA,
Leszyk JD,
Stanley BA,
Fox TE,
Stanley A,
Hall MJ,
Hampel H,
South CD,
de la Chapelle A,
Burt RW,
Jones DA,
Kopelovich L,
Yeung AT. Immunodepletion Plasma Proteomics by TripleTOF 5600 and Orbitrap Elite/LTQ-Orbitrap Velos/Q Exactive Mass Spectrometers.
Journal of Proteome Research. 2013 Oct;12(10)
:4351-4365. PMC ID:PMC 3817719. |
|
Hall MJ,
Manne SL,
Myers RE,
Keenan EM,
Balshem AM,
Weinberg DS. Predictors of patient uptake of colorectal cancer gene environment risk assessment.
Genome Med. 2012 Nov 29;4(11)
:92. PMC ID:PMC3580425. |
|
Adonizio C,
Gazzillo M,
Knezetic J,
Snyder C,
Lynch HT,
Rybak C,
Hall MJ,
Lowstuter K,
Eggington J,
Morris GJ. Thirty-nine-year-old with familial colon cancer, and variant of undetermined significance in MSH6.
Semin Oncol. 2012 Apr;39(2)
:125-31. |
|
Kindler HL,
Wroblewski K,
Wallace JA,
Hall MJ,
Locker G,
Nattam S,
Agamah E,
Stadler WM,
Vokes EE. Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium.
Investigational New Drugs. 2012 Feb;30(1)
:382-386. |
|
Hall MJ,
Ruth K,
Giri VN. Rates and predictors of colorectal cancer screening by race among motivated men participating in a prostate cancer risk assessment program.
Cancer. 2012 Jan;118(2)
:478-484. PMC ID:PMC3195866. |
|
Chun YS,
Cooper HS,
Cohen SJ,
Konski A,
Burtness B,
Denlinger CS,
Astsaturov I,
Hall MJ,
Hoffman JP. Significance of Pathologic Response to Preoperative Therapy in Pancreatic Cancer.
Annals of Surgical Oncology. 2011 Dec;18(13)
:3601-3607. |
|
Rybak C,
Hall MJ. Interpretation of genetic testing for lynch syndrome in patients with putative familial colorectal cancer.
J Natl Compr Canc Netw. 2011 Nov 1;9(11)
:1311-20. |
|
Hall MJ,
Manne SL,
Winkel G,
Chung DS,
Weinberg DS,
Meropol NJ. Effects of a Decision Support Intervention on Decisional Conflict Associated with Microsatellite Instability Testing.
Cancer Epidemiology Biomarkers & Prevention. 2011 Feb;20(2)
:249-254. PMC ID:PMC3076798. |
|
Hall MJ,
Reid JE,
Wenstrup RJ. Prevalence of BRCA1 and BRCA2 Mutations in Women with Breast Carcinoma In Situ and Referred for Genetic Testing.
Cancer Prev Res (Phila). 2010 Dec;3(12)
:1579-85. PMC ID:PMC3005273. |
|
Chun YS,
Milestone BN,
Watson JC,
Cohen SJ,
Burtness B,
Engstrom PF,
Haluszka O,
Tokar JL,
Hall MJ,
Denlinger CS,
Astsaturov I,
Hoffman JP. Defining Venous Involvement in Borderline Resectable Pancreatic Cancer.
Annals of Surgical Oncology. 2010 Nov;17(11)
:2832-2838. |
|
Hall MJ,
Egleston B,
Miller SM,
Buzaglo JS,
Millard J,
Ridgway C,
Damjanov N,
Sprandio JD,
Meropol NJ. Barriers to participation in cancer prevention clinical trials.
Acta Oncologica. 2010 Aug;49(6)
:757-766. PMC ID:PMC2901417. |
|
Hall MJ. Counterpoint: implementing population genetic screening for lynch syndrome among newly diagnosed colorectal cancer patients--will the ends justify the means?.
J Natl Compr Canc Netw. 2010 May;8(5)
:606-11. |
|
Gold HT,
Hall MJ,
Blinder V,
Schackman BR. Cost Effectiveness of Pharmacogenetic Testing for Uridine Diphosphate Glucuronosyltransferase 1A1 Before Irinotecan Administration for Metastatic Colorectal Cancer.
Cancer. 2009 Sep;115(17)
:3858-3867. PMC ID:PMC2853177. |
|
Forman AD,
Hall MJ. Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer.
Breast J. 2009 Sep-Oct;15 Suppl 1
:S56-62. |
|
Hall MJ,
Reid JE,
Burbidge LA,
Pruss D,
Deffenbaugh AM,
Frye C,
Wenstrup RJ,
Ward BE,
Scholl TA,
Noll WW. BRCA1 and BRCA2 Mutations in Women of Different Ethnicities Undergoing Testing for Hereditary Breast-Ovarian Cancer.
Cancer. 2009 May;115(10)
:2222-2233. PMC ID:PMC2771545. |
|
Allendorf JD,
Lauerman M,
Bill A,
DiGiorgi M,
Goetz N,
Vakiani E,
Remotti H,
Schrope B,
Sherman W,
Hall M,
Fine RL,
Chabot JA. Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: Feasibility, efficacy, and survival.
Journal of Gastrointestinal Surgery. 2008 Jan;12(1)
:91-100. |
|
Hershman D,
Hall MJ,
Wang XY,
Jacobson JS,
McBride R,
Grann VR,
Neugut AI. Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer.
Cancer. 2006 Dec;107(11)
:2581-2588. |
|
Faculty
Publications
